Foresee Pharmaceuticals Co., Ltd. (Foresee) is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Our mission is to provide patients with more medical options in comfort, compliance, convenience, and cure. We strive to improve patients' quality of life and provide cure through innovative research. Foresee's R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and the first-in-class NCE programs targeting rare and severe disease areas with high unmet needs.
Foresee has two core technologies:
- Drug Delivery Technology：stabilized injectable formulation (SIF), a sustained-release drug delivery platform
Our proprietary drug delivery technology (SIF), enables us to develop differentiated, ready-to-use long-acting injectable products through 505(b)(2) regulatory pathway. To date, the SIF delivery system has demonstrated its applications to small molecules and peptides, including in Foresee's approved and launched product CAMCEVI®. Products currently under development are FP-014 (Triptorelin, for prostate cancer), FP-016(neurology / psychiatry), FP-004 (Buprenorphine, for opioid dependence / pain), and FP-011 (Goserelin, for breast cancer), of which FP-004 and FP-011 are immediately available for partnering.
- Rational Drug Design：novel new drug (New Chemical Entity, NCE) development
Our rationally-designed small molecule candidates are focused on delivering new chemical entities (NCEs) ; products currently under development are FP-025 (MMP-12 inhibitor, for asthma / chronic obstructive pulmonary disease) and its follow-on compound FP-020 (sarcoidosis / idiopathic pulmonary fibrosis), FP-045 (ALDH2 activator, for Fanconi anemia / pulmonary hypertension associated with interstitial lung disease) and its follow-on compound FP-040 (CNS diseases).
Forsee's management team consists of seasoned pharmaceutical professionals with many years of industry experience in pharmaceutical R&D and management. To rapidly advance its pipeline products, Foresee has also teamed up with a network of advisors and consultants in the area of medical, legal, regulatory, business development, and commercial, among others. These advisors and consultants are industry veterans with significant experience and expertise in their respective fields and many are key opinion leaders (KOLs). Foresee has also established long-term partnerships with commercial contract development manufacturers (CDMOs) of drug substance and drug product, and other supply chain vendors to manage clinical trial materials and commercial supplies. In addition, Foresee has also partnered with established global and regional pharmaceutical companies to commercialize and launch their development-stage and approved products across the globe. These partnerships provide the resources and flexibility required to rapidly deliver our medicines to patients across the globe thus improving their standard of care.